Search Results - "Ladanyi, M."

Identifying patients with NTRK fusion cancer by Solomon, J P, Benayed, R, Hechtman, J F, Ladanyi, M

“…Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now…”
Get full text

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research by Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A.J., Bibeau, F., Dietel, M., Hechtman, J.F., Troiani, T., López-Rios, F., Douillard, J.-Y., Andrè, F., Reis-Filho, J.S.

“…NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most frequent mechanism of…”
Get full text

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer by Hastings, K., Yu, H.A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C.A., Liu, Z., Henick, B.S., Wurtz, A., Cai, G., Plodkowski, A.J., Long, N.M., Halpenny, D.F., Killam, J., Oliva, I., Schultz, N., Riely, G.J., Arcila, M.E., Ladanyi, M., Zelterman, D., Herbst, R.S., Goldberg, S.B., Awad, M.M., Garon, E.B., Gettinger, S., Hellmann, M.D., Politi, K.

“…Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however,…”
Get full text

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas by Schoenfeld, A.J., Rizvi, H., Bandlamudi, C., Sauter, J.L., Travis, W.D., Rekhtman, N., Plodkowski, A.J., Perez-Johnston, R., Sawan, P., Beras, A., Egger, J.V., Ladanyi, M., Arbour, K.C., Rudin, C.M., Riely, G.J., Taylor, B.S., Donoghue, M.T.A., Hellmann, M.D.

“…Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma,…”
Get full text

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research by Belli, C., Penault-Llorca, F., Ladanyi, M., Normanno, N., Scoazec, J.-Y., Lacroix, L., Reis-Filho, J.S., Subbiah, V., Gainor, J.F., Endris, V., Repetto, M., Drilon, A., Scarpa, A., André, F., Douillard, J.-Y., Curigliano, G.

“…Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities…”
Get full text

Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group by Mandelker, D., Donoghue, M., Talukdar, S., Bandlamudi, C., Srinivasan, P., Vivek, M., Jezdic, S., Hanson, H., Snape, K., Kulkarni, A., Hawkes, L., Douillard, J.-Y, Wallace, S.E., Rial-Sebbag, E., Meric-Bersntam, F., George, A., Chubb, D., Loveday, C., Ladanyi, M., Berger, M.F., Taylor, B.S., Turnbull, C.

“…It is increasingly common in oncology practice to perform tumour sequencing using large cancer panels. For pathogenic sequence variants in cancer…”
Get full text

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing by Yu, H.A., Arcila, M.E., Hellmann, M.D., Kris, M.G., Ladanyi, M., Riely, G.J.

“…EGFR T790M is the most common mutation associated with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Baseline EGFR T790M mutations in EGFR…”
Get full text

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) by Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D.M., Hechtman, J., Wei, G., Cam, N.R., Christiansen, J., Luo, D., Maneval, E.C., Bauer, T., Patel, M., Liu, S.V., Ou, S.H.I., Farago, A., Shaw, A., Shoemaker, R.F., Lim, J., Hornby, Z., Multani, P., Ladanyi, M., Berger, M., Katabi, N., Ghossein, R., Ho, A.L.

“…Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity. We report the case of a patient with an initial diagnosis of salivary…”
Get full text

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium by Li, B.T., Janku, F., Jung, B., Hou, C., Madwani, K., Alden, R., Razavi, P., Reis-Filho, J.S., Shen, R., Isbell, J.M., Blocker, A.W., Eattock, N., Gnerre, S., Satya, R.V., Xu, H., Zhao, C., Hall, M.P., Hu, Y., Sehnert, A.J., Brown, D., Ladanyi, M., Rudin, C.M., Hunkapiller, N., Feeney, N., Mills, G.B., Paweletz, C.P., Janne, P.A., Solit, D.B., Riely, G.J., Aravanis, A., Oxnard, G.R.

“…Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also…”
Get full text

Clinical and molecular characterization of patients with cancer of unknown primary in the modern era by Varghese, A.M., Arora, A., Capanu, M., Camacho, N., Won, H.H., Zehir, A., Gao, J., Chakravarty, D., Schultz, N., Klimstra, D.S., Ladanyi, M., Hyman, D.M., Solit, D.B., Berger, M.F., Saltz, L.B.

“…On the basis of historical data, patients with cancer of unknown primary (CUP) are generally assumed to have a dismal prognosis with overall survival of less…”
Get full text

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing by Terraf, P., Pareja, F., Brown, D.N., Ceyhan-Birsoy, O., Misyura, M., Rana, S., O’Reilly, E., Carlo, M.I., Aghajanian, C., Liu, Y., Derakhshan, F., Jayakumaran, G., Weigelt, B., Walsh, M., Stadler, Z., Offit, K., Ladanyi, M., Robson, M., Zehir, A., Reis-Filho, J.S., Mandelker, D.

“…Tumor-only sequencing, implemented for the identification of somatic variants, is oftentimes used for the detection of actionable germline variants. We sought…”
Get full text

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers by Drilon, A., Bergagnini, I., Delasos, L., Sabari, J., Woo, K.M., Plodkowski, A., Wang, L., Hellmann, M.D., Joubert, P., Sima, C.S., Smith, R., Somwar, R., Rekhtman, N., Ladanyi, M., Riely, G.J., Kris, M.G.

“…RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in…”
Get full text

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas by Selenica, P., Marra, A., Choudhury, N.J., Gazzo, A., Falcon, C.J., Patel, J., Pei, X., Zhu, Y., Ng, C.K.Y., Curry, M., Heller, G., Zhang, Y.-K., Berger, M.F., Ladanyi, M., Rudin, C.M., Chandarlapaty, S., Lovly, C.M., Reis-Filho, J.S., Yu, H.A.

“…Studies of targeted therapy resistance in lung cancer have primarily focused on single-gene alterations. Based on prior work implicating apolipoprotein b…”
Get full text

Hydration and Aggregation in Mono- and Disaccharide Aqueous Solutions by Gigahertz-to-Terahertz Light Scattering and Molecular Dynamics Simulations by Lupi, L, Comez, L, Paolantoni, M, Perticaroli, S, Sassi, P, Morresi, A, Ladanyi, B. M, Fioretto, D

“…The relaxation properties of hydration water around fructose, glucose, sucrose, and trehalose molecules have been studied by means of extended frequency range…”
Get full text

Dynamics of Biological Water: Insights from Molecular Modeling of Light Scattering in Aqueous Trehalose Solutions by Lupi, Laura, Comez, Lucia, Paolantoni, Marco, Fioretto, Daniele, Ladanyi, Branka M

“…Extended depolarized light scattering (EDLS) measurements have been recently employed to investigate the dynamics of water solvating biological molecules,…”
Get full text

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors by Chitale, D, Gong, Y, Taylor, B S, Broderick, S, Brennan, C, Somwar, R, Golas, B, Wang, L, Motoi, N, Szoke, J, Reinersman, J M, Major, J, Sander, C, Seshan, V E, Zakowski, M F, Rusch, V, Pao, W, Gerald, W, Ladanyi, M

“…To address the biological heterogeneity of lung cancer, we studied 199 lung adenocarcinomas by integrating genome-wide data on copy number alterations and gene…”
Get full text

Molecular Dynamics Simulations of the Interior of Aqueous Reverse Micelles by Faeder, J, Ladanyi, B. M

“…Aqueous reverse micelles, which are surfactant aggregates in nonpolar solvents that enclose packets of aqueous solution, have been widely studied…”
Get full text

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma by GIRARD, N, SIMA, C. S, ZAKOWSKI, M. F, LADANYI, M, RIELY, G, PAO, W, JACKMAN, D. M, SEQUIST, L. V, CHEN, H, YANG, J. C-H, JI, H, WALTMAN, B, ROSELL, R, TARON, M

“…Epidermal growth factor receptor (EGFR) tumour genotyping is crucial to guide treatment decisions regarding the use of EGFR tyrosine kinase inhibitors in…”
Get full text

Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers by Shukla, N., Levine, M. F., Gundem, G., Domenico, D., Spitzer, B., Bouvier, N., Arango-Ossa, J. E., Glodzik, D., Medina-Martínez, J. S., Bhanot, U., Gutiérrez-Abril, J., Zhou, Y., Fiala, E., Stockfisch, E., Li, S., Rodriguez-Sanchez, M. I., O’Donohue, T., Cobbs, C., Roehrl, M. H. A., Benhamida, J., Iglesias Cardenas, F., Ortiz, M., Kinnaman, M., Roberts, S., Ladanyi, M., Modak, S., Farouk-Sait, S., Slotkin, E., Karajannis, M. A., Dela Cruz, F., Glade Bender, J., Zehir, A., Viale, A., Walsh, M. F., Kung, A. L., Papaemmanuil, E.

“…The utility of cancer whole genome and transcriptome sequencing (cWGTS) in oncology is increasingly recognized. However, implementation of cWGTS is challenged…”
Get full text

Vibrational Spectroscopy and Dynamics of Water Confined inside Reverse Micelles by Pieniazek, Piotr A, Lin, Yu-Shan, Chowdhary, Janamejaya, Ladanyi, Branka M, Skinner, J. L

“…In this work, we combine atomistic molecular dynamics simulations with theoretical vibrational spectroscopy to study the properties of water confined inside…”
Get full text